湖南赛隆药业

Hunan Sailong Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Sailong Pharmaceutical Group Co., Ltd., specializing in the research, development, manufacturing, and commercialization of pharmaceutical products. Founded in 2007, the company's product portfolio primarily focuses on the nervous system, cardiovascular and cerebrovascular systems, and the digestive system. Key commercial products include esomeprazole sodium, pantoprazole sodium, argatroban, milrinone, parecoxib sodium, and various peptide-based or tissue-derived therapeutics like brain protein hydrolysate and thymosin alpha-1. Operating advanced manufacturing facilities that comply with GMP standards, the company provides high-quality freeze-dried powder injections, small-volume injections, and active pharmaceutical ingredients (APIs) to the domestic market.